Circulatory miR-133a and miR-145 are Associated with the Improving Impact of Combined Endurance Exercise and MitoQ on Cardiovascular Function in Patients with Hypertension

Abstract

We used mitoquinone (MitoQ), a mitochondria-targeted antioxidant, alone and combined with moderate ET (endurance training) in male patients with hypertension to determine their effects on blood pressure (BP), cardiac function, TOS (total oxidant status), and serum miR-145, miR-133a, and hs-CRP levels. Moderately HTN patients participated in groups of Placebo, MitoQ, ET, and MitoQ+ET. Serum was used to assess miR-133a, miR-145, TOS, and hs-CRP, and echocardiography was performed to assess cardiac performance. In the MitoQ+ET group, BP, left ventricular hypertrophy, and cardiac filling pressure decreased. Ejection fraction did not change significantly. Both MitoQ+ET and ET significantly reduced TOS and hs-CRP and significantly increased miR-145 and miR-133a in serum. Overall anti-inflammatory and antioxidant properties of ET and MitoQ were associated with miR-145 and miR-133a increase, and with cardiac function and BP improvements in patients with HTN. MitoQ+ET may potentially be used as an alternative therapy in HTN treatment. HIGHLIGHTS• MitoQ and endurance training (ET) improved blood pressure and cardiac function in patients with HTN.• MitoQ and ET increased expression of miR-145 and miR-133a.• Anti-inflammatory and antioxidant properties of ET and MitoQ linked to increased miRs-145 and 133a.